LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedLoading investors…
Activity from announced rounds
Develops fungal genome-derived therapeutics for organ transplant rejection
Develops hormonal and non-hormonal male contraceptives for men and couples globally
Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas
Powers the acceleration of clinical research to transform patient outcomes
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...
Develops medicines targeting historically undruggable protein targets in cancer
Provides AI-native due diligence for life sciences dealmaking